Surgical treatment of patients with malignant tumor complicated with coronary heart disease
10.3760/cma.j.cn431274-20250706-00897
- VernacularTitle:恶性肿瘤合并冠心病患者的外科治疗
- Author:
Hui XUE
1
;
Lixin FAN
1
;
Mingkui ZHANG
1
;
Qingyu WU
1
;
Yanbin SHAO
1
;
Zhengjie ZHANG
1
Author Information
1. 清华大学第一附属医院心脏中心，北京 100016
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Neoplasms;
Coronary artery bypass;
Cardio-oncology
- From:
Journal of Chinese Physician
2025;27(8):1138-1141
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the feasibility and clinical effect of surgical treatment for patients with malignant tumor complicated with coronary heart disease.Methods:The medical records of 12 patients with malignant solid tumor complicated with coronary heart disease who were treated by the same surgical team in the Department of Cardiac Surgery, the First Hospital of Tsinghua University from January 2018 to May 2025 were collected retrospectively, including 8 cases of digestive system tumors, 3 cases of lung tumors and 1 case of urinary system tumor. All patients underwent simultaneous (4 cases) or staged (8 cases) coronary artery bypass grafting and tumor resection. Coronary artery bypass grafting under cardiopulmonary bypass was performed in 2 cases, and off-pump coronary artery bypass grafting was performed in the remaining 10 cases. Postoperative follow-up was conducted.Results:None of the 12 patients died during hospitalization, and all were cured and discharged. No perioperative myocardial ischemia or infarction occurred during hospitalization, and no postoperative surgical bleeding occurred. The 12 patients were followed up for 1 month to 7 years and 5 months. One patient with rectal cancer complicated with coronary heart disease had liver and lung metastases 13 months after surgery and died suddenly during the second cycle of chemotherapy 16 months after surgery. The remaining 11 patients survived.Conclusions:It is feasible to perform coronary artery bypass grafting and tumor resection in patients with coronary heart disease complicated with malignant tumor, and the short-term and medium-term effects are satisfactory.
